Precision immunology company Scipher Medicine has introduced the ClinicalTrialRank.com AI platform to the public, designed to forecast the likelihood of clinical study failures.
This platform is set to change the drug development process by offering biopharma companies and investors the ability to make strategic decisions.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It acts as a pivotal resource for companies seeking to mitigate risks within their development pipelines, refine research and development portfolios, and manage investment capital.
The platform’s inception is the culmination of more than ten years of research and technological advancements by a team of scientists at the company.
According to Scipher, at the core of this platform is the human interactome, a map of protein-protein interactions, which serves as the foundation for the company’s disease models.
The platform’s technology is said to integrate genotype, phenotype, and treatment models with the interactome, facilitating a learning process from the network patterns of approved drugs and the therapeutic responses of individuals.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe multi-layered analysis provided by ClinicalTrialRank.com yields an accurate ranking of therapeutic targets, taking into account two pivotal factors: the targets’ connection to and impact on the genetic predisposition of diseases, and their capacity to restore the disturbed molecular profiles of patients to a normal state.
Scipher noted that it applied this technology across roughly 25 different disease domains.
Its internal evaluations have shown that targets with low rankings are almost invariably terminated before reaching the market.
This insight could have potentially averted around 1,000 halted trials across these domains.
Scipher Medicine CEO Reg Seeto stated: “The development model in bio-pharma is broken as too many drugs fail in the clinic. We need to better de-risk at each stage of development. Our commercial test, PrismRA, has already proven the ability to commercially de-risk development by predicting treatment response.
“With ClinicalTrialRank.com, we are now impacting both pre-clinical and clinical drug development. Our proven ability to predict clinical trial failure, combining network medicine, AI and proprietary data, means we enhance the overall probability of clinical development success, especially when clinical failures waste tens of billions of dollars each year.”
